VEGFA and neoplasm: MDSC formation is also reduced as an advantageous side-effect of several cancer cell-targeting therapies, such as the tyrosine kinase inhibitor sunitinib, via blockade of VEGF, and c-kit signaling (118, 119), or the cytotoxic drugs gemcitabine and 5-fluorouracil that induce selective apoptosis of MDSC in several tumor models, while leaving T cells, DCs, B cells and NK cells unharmed (120, 121).